



February 21, 2023

Notice to Covered Entities Regarding Refunds for Certain Daiichi Sankyo, Inc. Products

Daiichi Sankyo, Inc. (“DSI”) has recalculated 340B ceiling prices and will offer refunds to affected covered entities on certain DSI products for the periods listed below:

Period	NDC-11	Product Description
1Q 2020	65597-0406-01	Enhertu-100mg
1Q 2022	65597-0902-30	Welchol for Oral Suspension
4Q 2022	65597-0902-30	Welchol for Oral Suspension

DSI has asked the Office of Pharmacy Affairs within the Health Resources and Services Administration (“HRSA”) to post this notice on HRSA’s public website to ensure transparency by providing access to information about DSI’s refund procedures for the impacted DSI products.

DSI has determined the refund amount owed to each affected covered entity. DSI will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to issue refund checks in the appropriate amount to affected covered entities. If a covered entity believes they are due a refund and are not contacted by Apexus by June 21, 2023, you may contact Marc Carrier, Manager, Contract Operations & Government Price Reporting, at mcarrier@dsi.com.